CA
PRCT icon

Continuum Advisory’s Procept Biorobotics PRCT Stock Holding History

Continuum Advisory’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87K Buy
+83
New +$2.08K ﹤0.01% 1743
2025
Q2 		– Sell
-12
Closed -$699 – 1263
2025
Q1 		$699 Hold
12
– – ﹤0.01% 1553
2024
Q4 		$966 Hold
12
– – ﹤0.01% 1625
2024
Q3 		$1.03K Buy
+12
New +$853 ﹤0.01% 1615

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Continuum Advisory's PRCT Position: Q2 2026 in Review

Continuum Advisory opened a new position in Procept Biorobotics (PRCT) in Q2 2026: 83 shares worth $1.87K. The stake represents ﹤0.01% of the portfolio and ranks #1743 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in PRCT as recently as Q1 2025.

Continuum Advisory first reported a position in PRCT in Q3 2024 and has held it in 4 quarters since. 253 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Continuum Advisory held 83 shares of Procept Biorobotics worth $1.87K as of Q2 2026.
  • Procept Biorobotics was a new Continuum Advisory position in Q2 2026.
  • Procept Biorobotics made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1743 holding.
  • Continuum Advisory first reported a position in Procept Biorobotics in Q3 2024 and has held it in 4 quarters since.
  • 253 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.